Back to results
US 7,842,463 B2Granted
Method of diagnosing early stage renal impairment
AssigneeVitateq Biotechnology GmbH
InventorFlorian Kronenberg
Life of this patent
Estimating the term…
Abstract
There is disclosed a method of diagnosing early stage renal impairment in humans, characterized by the following steps: measuring the amount of apoA-IV in a body liquid or tissue sample of a human, and comparing the measured amount of apoA-IV with a reference value.
Claims17
A method of diagnosing early stage renal impairment in a human having a glomerular filtration rate (GFR) of more than 90 ml/min/1.73 m2, comprising:
- measuring an amount of apoA-IV in a plasma sample or a serum sample of the human;
- comparing the measured amount of apoA-IV with a reference value obtained from a human without renal impairment;
- and
- diagnosing early stage renal impairment based on the comparison of the measured amount of apoA-IV with the reference value, wherein early stage renal impairment is defined by a glomerular filtration rate (GFR) of more than 90 ml/min/1.73 m2, and wherein an early stage of a renal impairment in the human is diagnosed by way of an increased level of apoA-IV in the plasma sample or the serum sample as compared to the reference value obtained from a human without renal impairment.
1 more element
A method of diagnosing early stage renal impairment in a human having a glomerular filtration rate (GFR) of more than 90 ml/min/1.73 m2, comprising:
- measuring an amount of apoA-IV in a serum sample of the human;
- comparing the measured amount of apoA-IV with a reference value, wherein the reference value is between 10 and 18 mg of apoA-IV/dl of serum;
- and
- diagnosing early stage renal impairment based on the comparison of the measured amount of apoA-IV with the reference value, wherein early stage renal impairment is defined by a glomerular filtration rate (GFR) of more than 90 ml/min/1.73 m2, and wherein an early stage of a renal impairment in the human is diagnosed when the measured value of apoA-IV in the serum sample is higher than 18 mg of apoA-IV/dl of serum.
1 more element
Dependencies are inferred from the claim text.